Celltrion, achieved first $1 billion exports in Korea

Annual sales of Biosimilar exceed 1 trillion

Celltrion Healthcare announced on the 5th that it won '$1 Billion Export Tower award ' at the 56th Trade Day Ceremony hosted by the Korea International Trade Association.

 

Whole view of Celltrion Healthcare Headquarters

Celltrion Healthcare is the first Korean pharmaceutical bio company to surpass $1 billion in annual exports.

 

Only five companies have received more than $1 billion towers.

 

SK Trading International won $10 billion tower, and Hyundai Construction Equipment, Kumho P&B Chemicals, Nexen Tire received the $1 billion tower with Celltrion Healthcare.

 

Celltrion Healthcare is an affiliate of Celltrion and Chairman Seo, Jung-jin, Celltrion, is the largest shareholder (35.69% stake).

 

Celltrion Healthcare receives antibody biosimilar products from Celltrion and sells them to global distributors.

 

Celltrion Healthcare's sales represent the export of biosimilars developed by Celltrion.

 

Celltrion sells a total of three biosimilars in Europe and the United States, including ‘Remsima’, ‘Truxima’ and ‘Herzuma’.

 

Remsima's original drug is Janssen's Remicade.

 

'Truxima' and 'Herzuma' are Mabthera’s and Herceptin’s biosimilar products, respectively.

 

Celltrion Healthcare received a $1 billion export tower four years after winning the $300 million export tower in 2015 as biosimilar sales increased.

 

According to Celltrion Healthcare's quarterly report, the cumulative exports of the three biosimilars in the third quarter totaled ₩7,828 billion.

 

It was 57.9% higher than ₩4,956 billion in the same period last year.

 

Remsima's exports increased 60.1% yoy to ₩399 billion, and Truxima's exports soared 148.3% to ₩34.6 billon.

 

Although Herzuma's exports fell by 42.2%, Remsima's and Truxima's propaganda boosted exports.

 

According to the Ministry of Food and Drug Safety, ‘2018 Domestic Drug Production Imports and Exports’, total drug exports last year totaled $4.67 billion.

 

Celltrion Healthcare accounts for about 20% of annual drug exports.

 

On this day, Hyeong-ki Kim, the CEO of Celltrion Healthcare, received the prize of the Minister of Trade, Industry and Energy's commendation for leading Korea's pharmaceutical exports.

 

The CEO said, “Three biosimilar products have achieved great results in the global market, opening the era of ₩1 trillion in exports of pharmaceuticals to biopharmaceutical companies, and we will focus on expanding exports with the goal of winning the $ 2 billion Export Tower within the next 1-2 years”.